A novel virus lytic for Pseudomonas aeruginosa has been purified. Its viral particles have a siphoviral morphology with a head 60 nm in diameter and a noncontractile tail 184 nm long. The dsDNA genome consists of 16,449 bp, has cohesive 3' termini, and encodes 28 putative proteins in a single strain. The peptidoglycan endopeptidase encoded by ORF 16 was found to be the lytic enzyme of this virus. The recombinant, purified enzyme was active up to 55 °C in the pH range 6-9 against all tested isolates of P. aeruginosa, but, surprisingly, also against the distant Gram-positive micrococci Arthrobacter globiformis and A. pascens. Both this virus and its endolysin are further candidates for possible treatment against P. aeruginosa and probably also other bacteria.

Institute of Plant Molecular Biology Biology Centre of the Czech Academy of Sciences Branisovska 1160 31 370 05 Ceske Budejovice Czech Republic

Zobrazit více v PubMed

Hawkins C., Harper D., Burch D., Änggård E., Soothill J. Topical treatment of Pseudomonas aeruginosa otitis of dogs with a bacteriophage mixture: A before/after clinical trial. Vet. Microbiol. 2010;146:309–313. doi: 10.1016/j.vetmic.2010.05.014. PubMed DOI

Lyczak J.B., Cannon C.L., Pier G.B. Establishment of Pseudomonas aeruginosa infection: Lessons from a versatile opportunist. Microbes Infect. 2000;2:1051–1060. doi: 10.1016/S1286-4579(00)01259-4. PubMed DOI

Driscoll J.A., Brody S.L., Kollef M.H. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007;67:351–368. doi: 10.2165/00003495-200767030-00003. PubMed DOI

Bassetti M., Vena A., Croxatto A., Righi E., Guery B. How to manage Pseudomonas aeruginosa infections. Drugs Context. 2018;7:212527. doi: 10.7573/dic.212527. PubMed DOI PMC

Pang Z., Raudonis R., Glick B.R., Lin T.J., Cheng Z. Antibiotic resistance in Pseudomonas aeruginosa: Mechanisms and alternative therapeutic strategies. Biotechnol. Adv. 2019;37:177–192. doi: 10.1016/j.biotechadv.2018.11.013. PubMed DOI

Chatterjee M., Anju C.P., Biswas L., Anil K.V., Mohan G.C., Biswas R. Antibiotic resistance in Pseudomonas aeruginosa and alternative therapeutic options. Int. J. Med. Microbiol. 2016;306:48–58. doi: 10.1016/j.ijmm.2015.11.004. PubMed DOI

Rose T., Verbeken G., De Vos D., Merabishvili M., Vaneechoute M., Lavigne R., Jennes S., Zizi M., Pirnay J.-P. Experimental phage therapy of burn wound infection: Difficult first steps. Int. J. Burn. Trauma. 2014;4:66–73. PubMed PMC

Wright A., Hawkins C.H., Änggård E.E., Harper D.R. A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa: A preliminary report of efficacy. Clin. Otolaryngol. 2009;34:349–357. doi: 10.1111/j.1749-4486.2009.01973.x. PubMed DOI

Namonyo S., Carvalho G., Guo J., Weynberg K.D. Novel bacteriophages show activity against selected Australian clinical strains of Pseudomonas aeruginosa. Microorganisms. 2022;10:210. doi: 10.3390/microorganisms10020210. PubMed DOI PMC

Kamyab H., Torkashvand N., Shahverdi A.R., Khoshayand M.R., Sharifzadeh M., Sepehrizadeh Z. Isolation, characterization, and genomic analysis of vB_PaeS_TUMS_P81, a lytic bacteriophage against Pseudomonas aeruginosa. Virus Genes. 2023;59:132–141. doi: 10.1007/s11262-022-01954-0. PubMed DOI

Merabishvili M., Pirnay J.P., Verbeken G., Chanishvili N., Tediashvili M., Lashkhi N., Glonti T., Krylov V., Mast J., Van Parys L., et al. Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS ONE. 2009;4:e4944. doi: 10.1371/journal.pone.0004944. PubMed DOI PMC

Gontijo M.T.P., Jorge G.P., Brocchi M. Current status of endolysin-based treatments against Gram-negative bacteria. Antibiotics. 2021;10:1143. doi: 10.3390/antibiotics10101143. PubMed DOI PMC

Murray E., Draper L.A., Ross R.P., Hill C. The Advantages and challenges of using endolysins in a clinical setting. Viruses. 2021;13:680. doi: 10.3390/v13040680. PubMed DOI PMC

Fauconnier A. Phage therapy regulation. From night to dawn. Viruses. 2019;11:352. doi: 10.3390/v11040352. PubMed DOI PMC

Danis-Wlodarczyk K.M., Wozniak D.J., Abedon S.T. Treating bacterial infections with bacteriophage-based enzybiotics: In Vitro, In Vivo and clinical application. Antibiotics. 2021;10:1497. doi: 10.3390/antibiotics10121497. PubMed DOI PMC

Schmelcher M., Donovan D.M., Loessner M.J. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012;7:1147–1171. doi: 10.2217/fmb.12.97. PubMed DOI PMC

Larpin Y., Oechslin F., Moreillon P., Resch G., Entenza J.M., Mancini S. In vitro characterization of PlyE146, a novel phage lysin that targets Gram-negative bacteria. PLoS ONE. 2018;13:e0192507. doi: 10.1371/journal.pone.0192507. PubMed DOI PMC

Paradis-Bleau C., Cloutier I., Lemieux L., Sanschagrin F., Laroche J., Auger M., Garnier A., Levesque R.C. Peptidoglycan lytic activity of the Pseudomonas aeruginosa phage phiKZ gp144 lytic transglycosylase. FEMS Microbiol. Lett. 2007;266:201–209. doi: 10.1111/j.1574-6968.2006.00523.x. PubMed DOI

Guo M., Feng C., Ren J., Zhuang X., Zhang Y., Zhu Y., Dong K., He P., Guo X., Qin J. A novel antimicrobial endolysin, LysPA26, against Pseudomonas aeruginosa. Front Microbiol. 2017;8:293. doi: 10.3389/fmicb.2017.00293. PubMed DOI PMC

Petrzik K., Brázdová S., Krawczyk K. Novel viruses that lyse plant and human strains of Kosakonia cowanii. Viruses. 2021;13:1418. doi: 10.3390/v13081418. PubMed DOI PMC

Zhu W., Lomsadze A., Borodovsky M. Ab initio gene identification in metagenomic sequences. Nucleic Acids Res. 2010;38:e132. doi: 10.1093/nar/gkq275. PubMed DOI PMC

Brettin T., Davis J.J., Disz T., Edwards R.A., Gerdes S., Olsen G.J., Olson R., Overbeek R., Parrello B., Pusch G.D., et al. RASTtk: A modular and extensible implementation of the RAST algorithm for building custom annotation pipelines and annotating batches of genomes. Sci. Rep. UK. 2015;5:8365. doi: 10.1038/srep08365. PubMed DOI PMC

Zimmermann L., Stephens A., Nam S.Z., Rau D., Kübler J., Lozajic M., Gabler F., Söding J., Lupas A.N., Alva V. A completely reimplemented MPI bioinformatics toolkit with a new HHpred server at its core. Mol. Biol. Evol. 2018;430:S0022–S2836. doi: 10.1016/j.jmb.2017.12.007. PubMed DOI

Kumar S., Stecher G., Li M., Knyaz C., Tamura K. MEGA X: Molecular Evolutionary Genetics Analysis across computing platforms. Mol. Biol. Evol. 2018;35:1547–1549. doi: 10.1093/molbev/msy096. PubMed DOI PMC

Nishimura Y., Yoshida T., Kuronishi M., Uehara H., Ogata H., Goto S. ViPTree: The viral proteomic tree server. Bioinformatics. 2017;33:2379–2380. doi: 10.1093/bioinformatics/btx157. PubMed DOI

Briers Y., Volckaert G., Cornelissen A., Lagaert S., Michiels C.W., Hertveldt K., Lavigne R. Muralytic activity and modular structure of the endolysins of Pseudomonas aeruginosa bacteriophages fKZ and EL. Mol. Microbiol. 2007;65:1334–1344. doi: 10.1111/j.1365-2958.2007.05870.x. PubMed DOI

Mondal S.I., Akter A., Draper L.A., Ross R.P., Hill C. Characterization of an endolysin targeting Clostridioides difficile that affects spore outgrowth. Int. J. Mol. Sci. 2021;22:5690. doi: 10.3390/ijms22115690. PubMed DOI PMC

Russell D.A., Hatfull G.F. PhagesDB: The actinobacteriophage database. Bioinformatics. 2017;33:784–786. doi: 10.1093/bioinformatics/btw711. PubMed DOI PMC

Martin D.P., Varsani A., Roumagnac P., Botha G., Maslamoney S., Schwab T., Kelz Z., Kumar V., Murrell B. RDP5: A computer program for analyzing recombination in, and removing signals of recombination from, nucleotide sequence datasets. Virus Evol. 2020;7:veaa087. doi: 10.1093/ve/veaa087. PubMed DOI PMC

Ghose C., Euler C.W. Gram-negative bacterial lysins. Antibiotics. 2020;9:74. doi: 10.3390/antibiotics9020074. PubMed DOI PMC

Klyczek K.K., Bonilla J.A., Jacobs-Sera D., Adair T.L., Afram P., Allen K.G., Archambault M.L., Aziz R.M., Bagnasco F.G., Ball S.L., et al. Tales of diversity: Genomic and morphological characteristics of forty-six Arthrobacter phages. PLoS ONE. 2017;12:e0180517. doi: 10.1371/journal.pone.0180517. PubMed DOI PMC

Abdelkader K., Gerstmans H., Saafan A., Dishisha T., Briers Y. The preclinical and clinical progress of bacteriophages and their lytic enzymes: The parts are easier than the whole. Viruses. 2019;11:96. doi: 10.3390/v11020096. PubMed DOI PMC

Gondil V.S., Harjai K., Chhibber S. Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections. Int. J. Antimicrob. Agents. 2020;55:105844. doi: 10.1016/j.ijantimicag.2019.11.001. PubMed DOI